Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials.
Nahida Sakis, Liat Sorski, Eden Asraf...
https://pubmed.ncbi.nlm.nih.gov/42088573/Actively Recruiting
Led by Assaf-Harofeh Medical Center · Updated on 2019-04-18
200
Participants Needed
6
Research Sites
N/A
Total Duration
Researchers are studying colorectal cancer patients undergoing surgery to see if using two drugs together around the time of surgery can reduce cancer spread and improve survival. The study focuses on how stress-related chemicals released during the perioperative period may promote cancer progression and tests whether blocking these chemicals with propranolol and etodolac can have anti-metastatic effects. The trial is a Phase II, double-blind, placebo-controlled study involving 200 patients. Participants will take propranolol and etodolac orally for 20 days, starting five days before surgery. The propranolol dose changes over time, starting lower before surgery, increasing on surgery day, and tapering afterward. Etodolac is given consistently twice daily during the entire period. There is also a placebo group following the same schedule. The study compares the effects of the drug combination versus placebo in preventing cancer recurrence. During the trial, patients will be monitored for survival outcomes over five years, including disease-free survival and overall survival. Biological markers in tumor tissue and blood will be assessed about one year after surgery to understand anti- and pro-metastatic processes. Safety will be tracked through adverse events within 30 days post-surgery, and psychological health, including depression and fatigue, will also be evaluated before and after surgery. The total follow-up time extends to five years.
CONDITIONS
Colorectal Metastasis Prevention International Trial 2
O
Oded Zmora, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Assaf-Harofeh Medical Center
Lead Sponsor
Sheba Medical Center
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 20 days
Participants receive a perioperative combined drug regimen of propranolol and etodolac or placebo, starting 5 days before surgery and continuing for a total of 20 days around the time of surgery.
Several visits around surgery for medication administration and monitoring
Duration - Up to 5 years
Participants are monitored for disease-free survival and adverse events up to 5 years after surgery, including assessments at 30 days and approximately 1 year post-surgery.
Follow-up visits at baseline, 30 days, and periodic assessments up to 5 years
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Nahida Sakis, Liat Sorski, Eden Asraf...
https://pubmed.ncbi.nlm.nih.gov/42088573/Lee Shaashua, Maytal Shabat-Simon, Rita Haldar...
https://pubmed.ncbi.nlm.nih.gov/28490464/Rita Haldar, Lee Shaashua, Hagar Lavon...
https://pubmed.ncbi.nlm.nih.gov/29800703/Assaf-Harofeh Medical Center
Lead Sponsor
Sheba Medical Center
Collaborating Sponsor